Case Studies
Fast-tracking Market Entry to France
Discover how a Pharmaceutical Company can Cut 18 months off the Standard Timeline.
Fast-tracking Market Entry to France

Are you a biopharmaceutical company eager to launch your first EU-approved drug in France? Don't let the complex and lengthy process of establishing a compliant subsidiary slow you down.
Discover key insights on:
-
How a pharmaceutical company cut 18 months off the standard timeline for establishing its authorized local subsidiary in France.
-
The primary and secondary goals of rapidly setting up a compliant subsidiary and accessing local expertise without unnecessary recruitment.
-
The challenges of obtaining the "Exploitant" license and navigating the complex regulatory landscape in France.
-
The step-by-step process required to establish a subsidiary, including recruiting a Responsible Pharmacist, filing the dossier to ANSM, and more.
-
The successful outcome of entering the French market efficiently while maintaining regulatory compliance.
Download this Case Study
Discover our latest news

White Papers
5 Critical Considerations before your first EMA interaction
Get all the business experience needed for a successful first EMA interaction.

Expert Q&As
Expert Q&A - 1st Interactions with European Medicine Agency
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?

Case Studies
Early Access Programs in France
Explore Proven Strategies for a Quick Market Entry in France.